Ferring Highlights Commitment to C. Diff Infection Community on the Second Anniversary of the Launch of REBYOTA® (fecal ...

Recurrent Clostridium difficile (C diff) infection is a hard-to-treat gastrointestinal (GI) infection that causes 29,000 deaths every year in the US alone. Microbiome drug gets Breakthrough ...

FDA approved to prevent recurrent C. difficile infection (rCDI ... Home to help patients with rCDI across the U.S. receive treatment at home as well as health care settings Ferring continues ...

for the prevention of recurrent C. difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for C. diff infection. Launched on January 23, 2023 ...

The use of fecal microbiota, live-jslm (RBL; REBYOTA®) in the prevention of recurrent Clostridioides difficile infection ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

Recurrent miscarriage or fetal loss syndrome ... as well as diagnostic procedures and treatment considerations.

Recurrent aphthous ulcer (RAU ... anti-inflammatory and anti-allergic agent that has been evaluated for the treatment of RAU in a series of robust clinical trials. After a 100mg dose of 5% ...